Loading

logo

Journal of Clinical Haematology

ISSN: 2766-4686

Review Article Open Access
Volume 4 | Issue 1 | DOI: https://doi.org/10.33696/haematology.4.053

A Rare Blood Malignancy in a Genetic Hematological Disorder: Polycythemia Vera (PV) in Sickle Cell Disease (SCD)

Christopher L. Edwards1,2,3,4,*, Sharena Scott1,2, Michaela Boggan1,2,3, Jordan Meek1,2,3,4, W. Jeff Bryson2,5, Alexandria McDougald1,2, Milo Broadnax1,2, Camela S. Barker2,5,15, Jessica Miller1,2,6, John J. Sollers1,2,3,4, Tanisha Burford1,2,3, Jonathan Livingston1,2,3,4, Elaine Whitworth2,6, Goldie S. Byrd2,7,8, Kelvin L. Williams2,7, Sherry Eaton1,2,3,4, Malik Muhammad1,2,3,4, George Cliette1,2,4, Dana Jones2,9, Brianna Downey1,2,5,6, Hilary T. Dietahin1,2, Merrell Turner1,2, Roland Thorpe10, Keith Whitfield2,11, Debra O. Parker1,2, Elwood Robinson2,12, Mary Wood2,13, Kenyon Railey3, Shiv Sudhakar2,14, Wandy Morel Cubilete2,13, Nirmish Shah13
  • 1Debra O. Parker Research Incubator, North Carolina Central University, NC, USA
  • 2Psychoneuroendocrine Rare Diseases Laboratory, North Carolina Central University, NC, USA
  • 3Psychophysiology and Cardiovascular Health Laboratory, North Carolina Central University, NC, USA
  • 4Community Health Psychology Laboratory, North Carolina Central University, NC, USA
  • 5Clinical Psychology Program, Fielding Graduate University, CA, USA
  • 6Bridges Point Sickle Cell Foundation, NC, USA
  • 7Maya Angelou Center for Health Equity, Wake Forest Medical Center, NC, USA
  • 8Social Sciences and Health Policy, Wake Forest Medical Center, NC, USA
  • 9School of Law, North Carolina Central University, NC, USA
  • 10School of Public Health, Johns Hopkins University, MD, USA
  • 11University of Nevada, Las Vegas, NV, USA
  • 12Winston Salem State University, NC, USA
  • 13Duke University Medical Center, NC, USA
  • 14California Northstate University, CA, USA
  • 15Rochester Institute of Technology, NY, USA
+ Affiliations - Affiliations

Corresponding Author

Dr. Christopher L. Edwards, cedwards@nccu.edu

Received Date: July 13, 2023

Accepted Date: August 07, 2023

Citation:

Edwards CL, Scott S, Boggan M, Meek J, Bryson WJ, McDougald A, et al. A Rare Blood Malignancy in a Genetic Hematological Disorder: Polycythemia Vera (PV) in Sickle Cell Disease (SCD). J Clin Haematol. 2023;4(1):9-19.


Copyright: © 2023 Edwards CL, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Objective: To delineate the etiology, symptomatology, and treatment of Polycythemia Vera in adults with Sickle Cell Disease. The current review contains a review of the 4 case reports that we found on the topic. To our knowledge, no other case reports exist.

Methods: We reviewed the scientific literature to discover case reports that included the topic of PV. We noted consistencies in presentation, evaluation, treatment, and clinical outcomes.

Results: We reviewed 4 case reports and a limited number of clinical papers on PV in SCD. We found and reported on consistencies in clinical presentation and the diversity of treatments. We reported hematological, bone marrow, and radiographic findings.

Conclusions: There is great variability in the evaluation and treatment of cases of PV in SCD. We advocate for more research and deconstructing the complicated relationship between these two comorbid disorders.

Keywords

Polycythemia Vera, Sickle Cell Disease, Case reports

Recommended Articles

Gene Therapy for Sickle Cell Disease: Start of a New Era

This manuscript reviews treatment of Sickle Cell disease over time. The application of allogeneic stem cells proved the sickle cell disease could be permanently corrected and cured but limited to those with a compatible donor.

Needed, Assays for “Fetal Hemoglobin levels” in RBCs: Fetomaternal Hemorrhage and Expanded Applications in Sickle Cell Disease Management Could Forge an Evolution in Cellular Diagnostics

Treatment of sickle cell disease (SCD) remains varied with only a minority of patients benefiting from stem cell transplant as a near cure. Others await the promise of more effective and less toxic treatments than hydroxyurea, especially children who are most susceptible to the morbidities and mortalities of SCD. The recent report of Hebert, Rakotoson et al. points to an evolution of in vitro diagnostics (IVD) testing of blood cells with the emerging need for cell-by-cell measurement of red blood cell (RBC) specific hemoglobin variant levels. The study further provides clinical validation as to the utility of measuring HbF content in RBCs of SCD patients, not just as a prognostic test, but likely serving as a companion diagnostic in phase 3 clinical trials of new SCD therapies. 

Preventing Stroke in Sickle Cell Disease: 2021. The Role of Transcranial Doppler Ultrasound (TCD) When the Use of Transfusion is Problematic

While TCD is an indicator of risk, not a biopsy diagnosis (such as proof of cancer), at some point in the velocity spectrum the high velocity detected by TCD reaches what many believe is an unacceptable risk of stroke.

Phlebotomy in Congenital Erythrocytosis and in Sickle Cell Disease HbSC

The inherited haemoglobin disorders, including thalassemias and haemoglobinopathies, are the most common genetic diseases and the clinical laboratory is essential in the diagnosis. Haemoglobinopathies are monogenic disorders in the genes that encode globin chains that can lead to a defective globin production or a variant in the haemoglobin structure.

A Rare Blood Malignancy in a Genetic Hematological Disorder: Polycythemia Vera (PV) in Sickle Cell Disease (SCD)

To delineate the etiology, symptomatology, and treatment of Polycythemia Vera in adults with Sickle Cell Disease. The current review contains a review of the 4 case reports that we found on the topic. To our knowledge, no other case reports exist.

Full Text
Cite
Download PDF
Author Information X

About Scientific Archives

Scientific Archives is a global publisher initiated with the mission of ensuring equal opportunity for accessing science to research community all over the world. Spreading research findings with great relevance to all channels without any barrier is our goal. We want to overcome the challenges of Open Access with ensured quality and transparency.

Read More